Capitalizing on insights from human genetics to identify novel therapeutic targets for coronary artery disease

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Coronary artery disease (CAD) is a major cause of morbidity and mortality. Unfortunately, despite decades of research focused on disease pathogenesis, we still lack a sufficient pharmacopeia for preventing CAD. The failure of many novel cardiovascular drugs to improve clinical outcomes reflects the major substantial challenge of drug development: Identifying causal mechanisms that can be therapeutically manipulated to lower disease risk. Identifying genetic variants that are associated with risk of CAD has emerged as a clear path toward improving our understanding of the underlying mechanisms that lead to disease and to the development of new therapies. Here, we review the potential utility and limitations of using human genetics to guide the identification of therapeutic targets for CAD.

Original languageEnglish
Pages (from-to)19-32
Number of pages14
JournalAnnual review of medicine
Volume70
DOIs
StatePublished - Jan 27 2019

Keywords

  • coronary artery disease
  • drug development
  • genetics of complex disease

Fingerprint

Dive into the research topics of 'Capitalizing on insights from human genetics to identify novel therapeutic targets for coronary artery disease'. Together they form a unique fingerprint.

Cite this